

## SEMINARIO WEB

Conferencia *La ivermectina como preventivo ante el COVID-19*

Dr. Miguel Sierra Hoffmann  
Dr. Fernando Valerio

Fecha: sábado 13 de marzo de 2021; Hora: 5:00 pm

### GALERIA DE IMÁGENES DEL SEMINARIO WEB



Zoom Meeting

Recording LIVE on Facebook

# Ensayo Catracho : Ivermectina, realidades vs mitos

Miguel Sierra Hoffman MD  
&  
Fernando Valero MD

Martha Calderon

Jackeline Alger...

Maria Luisa Matute...

Jorge García (A...

Participants (92)

Find a participant

- JA Jackeline Alger (AHPA) (Me)
- CD Colegio de Microbiolog... (Host)
- M arsi (Co-host)
- ML Maria Luisa Matute (A... (Co-host)

Chat

preguntas en este chat  
El Dr. Jorge García, miembro de la Junta Directiva AHPA dio la bienvenida  
En estos momentos la Dra. María Luisa Matute, Presidenta AHPA, presenta el objetivo del seminario web, brinda agradecimientos  
En estos momentos presenta la hoja de vida del Dr. Miguel Sierra Hoffmann

Zoom Meeting

Recording LIVE on Facebook

**Nuevo campo de Batalla 2021**

Host inflammatory response phase

Stage I (Early Infection)	Stage II (Pulmonary Phase)	Stage III (Hyperinflammation Phase)
<b>Clinical Symptoms</b> Mild constitutional symptoms (Fever, SOB, CT), Dry Cough, Myalgia, Headache	<b>Time course</b> Worsening of breathlessness (PICO/PO2/SPO2/oxygen)	<b>ARDS</b> ARDS/Trans Lung Failure
<b>Clinical Signs</b> Lymphopenia, increased proinflammatory (D-dimer and D-DT) (DVT)	<b>Abnormal chest imaging</b> Bilateral opacities Low overall productivity	<b>Abnormal inflammatory markers</b> CRP, LDH, IL-6, IL-8, ferritin Thrombocytopenia, AT-protein elevation
<b>Potential Therapies</b> Antivirals, Antimalarials, Nucleoside analogues, and Caspase/serpin protease Reduce immunosuppression      Corticosteroids, JAK2 immunomodulators, IL-2 inhibitors, IL-1 inhibitors, and IL-6 inhibitors		

Fig. 1. COVID-19 pathogenesis phases and potential therapeutic targets (modified and adapted from Siddiq and Malik, 2020 [10]).

Fernando Valero

Jackeline Alger...

Margarita

Participants (100)

Find a participant

- JA Jackeline Alger (AHPA) (Me)
- CD Colegio de Microbiolog... (Host)
- M arsi (Co-host)
- CD Colegio de Micro... (Co-host)

Chat

A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients  
<https://doi.org/10.1371/journal.pone.0245025>

From Me to Everyone  
Los invitamos a realizar sus comentarios y preguntas en este chat.

To: Everyone

Type message here.

# Statistical Process Control

Pasteur and parachutes: when statistical process control is better than a randomized controlled trial

M Diaz, O Neufhauer

Stat Sci Health Care 2005;34:148-152. doi: 10.1186/s12874-005-0120-0




Figure 1. Control chart for the number of deaths over time. This chart indicates that there is still a lot of room for improvement. To decrease the mean of the process, you can't do it by itself; you have to control the process before day 400. The graph shows you're already over the control limit of the process (LL and UL), which means all the points lie outside the control limits (before day 400).



Tito Alvarado

Jackeline Alger...



msh



Fernando Valerio